Synthetic studies on amphidinolides C and F: synthesis of the C18-C29 segment of amphidinolide F by Armstrong, A & Pyrkotis, C
Graphical Abstract 
 
 
Synthetic studies on amphidinolides C and F: synthesis of the 
C18-C29 segment of amphidinolide F 
Alan Armstrong,* Constantina Pyrkotis 
 
 
Leave this area blank for abstract info. 
 Tetrahedron Letters  1
Synthetic studies on amphidinolides C and F: synthesis of the 
C18-C29 segment of amphidinolide F 
Alan Armstrong,* Constantina Pyrkotis 
 
Department of Chemistry, Imperial College London, South Kensington, London SW7 2AZ, UK  
Fax: +44 (0) 20 75945804 
E-mail: a.armstrong@imperial.ac.uk 
 
 
Abstract—The C18-C29 segment of amphidinolide F is synthesized in 12 steps from 1,4-butanediol. Key steps include a mono-Sharpless 
dihydroxylation of a dienoate, iodocyclisation to construct the trans-THF ring, and an E-selective Wittig reaction to introduce the C25-C26 
olefin. 
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The amphidinolides
1
 are a structurally diverse family of 
cytotoxic marine compounds which occur naturally in only 
minute amounts; total synthesis therefore becomes an 
important potential source. Although successful routes to 
several members of the family have been reported,
1,2
 this 
feat has not yet been accomplished for the closely related 
amphidinolides C
3
 and F
4
 (Figure 1). Amphidinolide C, in 
particular, exhibits highly potent cytotoxic activity against 
L1210 and KB cells in vitro (values of 0.0058 and 0.0046 
μg/ml, respectively), making a synthetic route to 
amphidinolides of this class an important goal. To date, 
three groups have reported studies towards the synthesis of 
fragments of these compounds.
3b, 3d, 5
 Here we describe our 
own approach, leading to a concise synthesis of the C18-
C29 THF unit of amphidinolide F. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structures of Amphidinolides C, C2 and F. 
We envisaged key bond disconnections across the diene at 
C9-C10 and the macrolactone, as well as at C17-C18. 
These led us to require the THF fragment 1 (Scheme 1), 
which could be obtained by appropriate manipulation of the 
α-hydroxy-diester 2. Diester 2 could in principle be 
accessed directly via a desymmetrising mono-Sharpless 
AD/Michael reaction on symmetrical dienoate 3. In the 
forward sense, this process would raise interesting 
questions of regio- and stereocontrol (vide infra), but it 
would potentially provide a highly concise route to the key 
intermediate 2. 
 
 
 
 
 
 
 
Scheme 1 
We first required an efficient route for the synthesis of 
diene dioate 3. Of several methods evaluated, the two 
proving most efficient in our hands are shown in Scheme 2. 
Hydrolysis of 2,5-dimethoxytetrahydrofuran 4 gave the  
dialdehyde 5 which underwent double Wittig reaction to 
give 3
6
 in 36% overall yield (E,E:E,Z = 92:8) from 4. The 
low yield is believed to be at least partly due to the 
volatility and water miscibility of 5. A higher overall yield 
was obtained in a sequential oxidation/olefination process 
using methodology recently reported by Graham.
7 
Thus, in 
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situ MnO2 monooxidation/olefination of diol 6 afforded 7, 
which was isolated and purified before application of a 
second oxidation/olefination step, this time using PCC as 
oxidant, to give 3 (65% overall) with similar 
stereoselectivity (E,E:E,Z = 92:8).  
 
With dienoate 3 in hand, we could now study the key 
conversion to THF 2. Ideally, this would be effected 
directly via a novel one-pot Sharpless AD/Michael 
reaction. Mono- versus bis-dihydroxylation of the diene 
was a potential concern. While we could not find direct 
literature precedent for selective mono-AD on 2,6-
dienoates, there was literature precedent for mono-
dihydroxylation of this type of substrate under Upjohn 
conditions.
8
 Additionally, we hoped that in situ Michael 
reaction of the initially formed AD product would remove 
the potentially reactive second alkene before any second 
dihydroxylation could take place.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Reagents and Conditions: (a) HCl (aq), THF, reflux, 2 h; 
(b) Ph3P=CHCO2Et, 3 Å MS, CH2Cl2, r.t., 36 h, 36%; (c) MnO2, 
Ph3P=CHCO2Et, 48 h, 95%; (d) PCC, imidazole, Ph3P=CHCO2Et, 19 
h, 65%. 
Table 1. Dihydroxylation/Cyclisation of Dienoate 3 
 
 
 
a
Determined by 
1
H NMR analysis. Major isomer is the trans-THF by 
correlation with products from the iodocyclization route. 
bEnt-8 and ent-2 
obtained in this experiment.  
 
For the cyclisation step, we envisaged that the desired 5-
exo-trig cyclisation mode would be kinetically preferred 
over the alternative possible 6-exo-trig.
9
 A further key 
question involved stereoselectivity in the Michael reaction, 
given the lack of stereocentres in the linking chain between 
C20 and C23. In one relevant precedent, Kobayashi 
observed non-diastereoselective cyclisation in a Michael 
reaction as part of his synthesis of the amphidinolide C17-
C29 fragment.
3d
 While this was not encouraging, we hoped 
that use of alternative cyclisation conditions would allow 
improved stereocontrol. Application of standard Sharpless 
AD conditions
10
 to 3 with 1 equivalent of AD-mix-β (Table 
1, entry 1) in the presence of methanesulfonamide effected 
complete reaction in < 2 h. The diol 8 was isolated in 85% 
yield together with 10% of the THF 2, which was obtained 
as a 3:2 mixture of diastereoisomers according to 
1
H NMR 
analysis. The enantiomeric excess of diol 8 was determined 
by chiral HPLC and found to be 73%. For comparison AD 
was also carried out with AD-mix-α (entry 2). Interestingly, 
this gave diol ent-8 of lower ee (57% ee), despite the fact 
that the quinidine and quinine-derived ligands in the two 
AD-mixes usually behave as “pseudoenantiomers”, giving 
products of similar enantiomeric excess. We next attempted 
the AD reaction in the presence of additional base in an 
attempt to promote the cyclisation reaction (entries 3 and 
4). While conversion was high and the THF 2 was now the 
major product, the yield was low, suggesting base-mediated 
decomposition. Moreover, the diastereoselectivity was 
consistently low (3:2). Since we had been able to isolate 
only low amounts of THF 2, but good yields of diol 8, we 
decided to investigate the cyclisation step separately. 
Treatment of 8 with 1 equiv of EtONa in EtOH/THF for 2 h 
gave 2 in 50% yield, again as a 3:2 mixture of 
diastereoisomers. Aprotic conditions (LHMDS in THF) 
gave very low conversion and an unchanged stereoisomeric 
ratio. We were able to separate small quantities of the two 
diastereomers, and re-submission of these to base allowed 
us to tentatively conclude that the minor, cis-diastereomer 
was thermodynamically preferred. We therefore decided to 
abandon the Michael addition and investigate alternative 
methods for THF formation. 
 
 
 
 
 
 
 
 
 
 
 
Iodocyclisation has been widely employed for THF 
synthesis
11
 and was an attractive option. This was first 
attempted with the “unnatural” diol, ent-8 (Scheme 3), 
affording a 3:1 mixture of trans and cis furans ent-9b and 
Entry AD-mix Additive Time (h) Yield 8 (%) Yield 2 (%) 2 trans:cisa 
1  - 2 85 10 3:2 
2
b
  - 2 82 12 3:2 
3  DBU (2 eq) 18 - 35 3:2 
4  NaOH (2 eq) 8 - 40 3:2 
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ent-9a. Separation of the two diastereoisomers using flash 
chromatography gave the trans-diastereoisomer ent-9b as a 
pale yellow semi-crystalline solid, recrystallisation of 
which resulted in enhanced ee (93%) according to chiral 
HPLC analysis. X-ray crystallography
12
 verified both the 
relative and the absolute configuration of ent-9b. 
 
 
 
 
 
 
 
Scheme 3 
We repeated the iodocyclisation with 8 itself (Scheme 3) to 
obtain 9b. Resolution during recrystallisation again resulted  
in enrichment from 73% to over 93% ee.
13
 The improved 
cyclisation diastereoselectivity (albeit in a still-moderate 
3:1 ratio), the significantly increased overall yield and the 
opportunity to improve the enantiomeric excess via 
resolution during the recrystallisation meant that the 
iodocyclisation approach towards the synthesis of this 
fragment was preferable to the earlier, base-mediated 
cyclisation. 
Having desymmetrised the diene dioate 3, we were now in 
a position to install the required functionality at either side 
of the THF unit (Scheme 4). Deiodination of 9b could be 
effected efficiently using either tributyltin/cat. AIBN in 
toluene at 50 
o
C or with indium hydride,
14
 generated from 
NaBH4/cat. InCl3. Differentiation of the two ethyl esters 
was now accomplished by selective reduction of the -
hydroxy ester
15
 using BH3.SMe2 /cat. NaBH4. Hydroxy 
group differentiation was achieved by bis-TBS ether 
formation and selective primary deprotection, affording 11. 
Dess-Martin oxidation in the presence of 1 equiv of H2O
16
 
afforded an unstable aldehyde in 80% yield which was then 
subjected to an E-selective olefination
17
 with a 
tributylphosphonium ylide to provide 12
18
 (43% from 
alcohol 11; 87:13, E:Z). The E-isomer was distinguished 
from the minor Z-isomer by coupling constant analysis (J 
H25-H26 = 15.1 vs 11.3 Hz). Reduction of the ethyl ester 
with DIBAL-H gave the corresponding aldehyde which 
was then converted to the 1,3-dithiane 1.
19
 Use of BF3.OEt2 
as Lewis acid in this step afforded 1 in only moderate 
yields due to competitive cleavage of the TBS ether. 
However, use of the milder Lewis acid MgBr2.OEt2 solved 
this problem, leading to formation of 1 (87:13, E:Z) in 75% 
yield (over two steps). 
 
 
 
 
 
 
 
Scheme 4. Reagents and Conditions: (a) AIBN, nBu3SnH, toluene, reflux, 
1 h, 95% or InCl3, cat. NaBH4, CH3CN, 3 h, 73%; (b) (i) BH3∙SMe2/THF, 
r.t.; (ii) NaBH4; (iii) EtOH, TsOH, 60% (+ 18% starting material); (c) (i) 
TBSCl, imidazole DMF, r.t., overnight, 81%; (ii) HF.pyridine, pyridine, 
THF, r.t., 8 h, 86%; (d) Dess-Martin periodinane, CH2Cl2 (wet), rt, 5-15 
min; (e) Me2C=CHCH2P
+
Bu3Br
-
, nBuLi (in hexanes), DMSO, toluene, -78 
ºC to 0 ºC, 43% (over two steps), 87:13 E:Z; (f) DIBAL-H, THF, -78º C, 1 
h; (g) HS(CH2)3SH, MgBr2∙OEt2, CH2Cl2, r.t., 1 h, 75% (over two steps). 
Finally, we have performed preliminary studies 
demonstrating the feasibility of converting the 
amphidinolide F side-chain into that of amphidinolide C, 
via selective allylic oxidation at C29 (Scheme 5). We could 
find little literature precedent for SeO2-mediated allylic 
oxidation
20
 of acyclic 1,3-dienes, and this process could 
potentially result in a mixture of regioisomeric products. In 
the event, 12 underwent SeO2 allylic oxidation to give, 
after chromatography, the desired allylic alcohol 13
21
 (ca. 
70%; E,E-configuration confirmed by NOE analysis), along 
with a 2:1 mixture assigned tentatively by 
1
H NMR as 
aldehyde 14 and regioisomeric allylic alcohols 15. This key 
transformation potentially allows access into amphidinolide 
C and analogues bearing unnatural side-chains at C29.  
 
 
 
 
 
Scheme 5 (a) SeO2, 
t
BuOOH, CH2Cl2, r.t., overnight. 
In conclusion, we have achieved a synthesis of the C18-
C29 fragment 1 of amphidinolide F in twelve steps starting 
from commercially available butane-1,4-diol 6. We have 
also demonstrated potential for further elaboration to 
amphidinolide C and analogues via oxidation at C29. 
Further studies towards these targets are currently 
underway. 
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